Help | RSS Feed



Cell Therapeutics, Inc. (NASD:CTIC) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Cell Therapeutics, Inc. (NASD:CTIC) seasonal charts above shows that a Buy Date of March 10 and a Sell Date of June 2 has resulted in a geometric average return of 0.47% above the benchmark rate of the S&P 500 Total Return Index over the past 17 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 17 years by an average of 100.47% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. The company’s therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

To download CTIC seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore